HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer

Despite advances in breast cancer treatment, residual disease driven by dormant tumor cells continues to be a significant clinical problem. Leukemia inhibitory factor receptor (LIFR) promotes a dormancy phenotype in breast cancer cells and LIFR loss is correlated with poor patient survival. Herein w...

Descripción completa

Detalles Bibliográficos
Autores principales: Clements, Miranda E., Holtslander, Lauren, Edwards, Courtney, Todd, Vera, Dooyema, Samuel D.R., Bullock, Kennady, Bergdorf, Kensey, Zahnow, Cynthia A., Connolly, Roisin M., Johnson, Rachelle W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403155/
https://www.ncbi.nlm.nih.gov/pubmed/34247191
http://dx.doi.org/10.1038/s41388-021-01931-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403155/
https://www.ncbi.nlm.nih.gov/pubmed/34247191
http://dx.doi.org/10.1038/s41388-021-01931-1

Ejemplares similares